C2i Genomics Partners with OncoDNA to Bring AI-Powered Liquid Biopsy for Cancer Diagnostics Across Europe
THIS PARTNERSHIP MARKS C2i'S LAUNCH INTO THE EU AND A FIRST-OF-ITS KIND INTERVENTIONAL CLINICAL TRIAL LED BY THE GUSTAVE ROUSSY INSTITUTE IN FRANCE
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects. This partnership will also support a first-of-its-kind interventional clinical trial in France led by Gustave Roussy.
As of 2021, the American Cancer Society reports that Europe accounts for 22.8% of the world’s total cancer cases and 19.6% of cancer deaths, but currently, there are few local genomic providers of cancer detection and treatment monitoring that operate in the EU market. OncoDNA, amongst others, has been providing tissue-based biomarker testing and personalized liquid biopsy to support oncologists in their clinical recommendations. The C2-intelligence platform, which uses AI-pattern recognition and whole-genome analysis, will use advanced cancer genomics and liquid biopsy products to support rapid and accurate detection of cancer, monitor disease progression and evaluate therapeutic efficacy in clinical research settings. This is all done to enable informed and timely personalized treatment decisions and support the development of more effective cancer treatments through pharma drug development partnerships.
“OncoDNA’s extensive lab operation, data interpretation infrastructure alongside its commercial expertise in bringing advanced cancer genomics and liquid biopsy products to market will help accelerate C2i’s expansion and commercialization in Europe,” said Asaf Zviran, CEO and Co-Founder of C2i Genomics. “This partnership will support clinical and pharma research services, and will ultimately provide the C2-intelligence platform for clinical research use.”
As part of the partnership, C2i and OncoDNA will collaborate on a 750+ patient interventional clinical trial led by Gustave Roussy leading comprehensive cancer center in Europe. C2i, with the help of OncoDNA, will provide cancer monitoring and analytic services to test the clinical utility of escalating metastatic treatment to patients with a high risk of cancer recurrence after standard of care. This basket trial will include detection of circulating tumor DNA (ctDNA) across various solid tumors, including lung cancer, breast cancer, sarcoma and gastrointestinal (GI) cancers. The study aims to provide conclusive evidence of the clinical and economic benefits of C2i’s cancer detection technology across various solid cancers.
“OncoDNA shares with C2i the vision of making precision medicine in oncology a reality for patients, allowing for more effective and individualized therapy decisions,” said Jean-Pol Detiffe, Chief Strategy & Innovation Officer, and Founder of OncoDNA. “C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminating the need to develop a patient-specific assay, and allowing rapid and high throughput solution for cancer patients across the EU. This partnership completes our offering of genomic services, NGS tests and data interpretation software suite.”
This partnership is C2i’s first commercial entry into the European market. It comes after a year of tremendous global growth and expansion, namely into South East Asia through a partnership with NovogeneAIT, into the U.S. with Premier Inc. and the Chinese market with NuProbe Global.
For companies interested in deploying the C2-Intelligence Platform, please visit www.c2i-genomics.com.
OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA grew into a corporate group of companies with world-renown expertise. The Group offers a unique portfolio that combines NGS services, biomarker testing, data interpretation software, and clinical decision support tools. OncoDNA is headquartered in Belgium, and its entities – BioSequence and IntegraGen – are based in Spain and France. The Group employs over 100 employees across 9 countries, works with an international network of 35 distributors and collaborates with both European-based and US-based subcontracted accredited laboratories. For further information, visit www.oncodna.com and connect through LinkedIn, Facebook or Twitter.
ABOUT C2i GENOMICS
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide up to 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. For more information, please visit www.c2i-genomics.com.
ABOUT GUSTAVE ROUSSY
Classed as the leading European Cancer Centre and the fifth on the world stage, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 3,200 health professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: a quarter of patients treated are included in clinical trials. For further information: www.gustaveroussy.fr/en, Twitter, Facebook, LinkedIn, Instagram.